

UBE2L3 (UbcH7) [untagged]

E2 – Ubiquitin Conjugating Enzyme

Alternate Names: E2-F1, EC 6.3.2.19, L-UBC, UbcH7, UbcM4, Ubiquitin conjugating enzyme E2-18 kDa UbcH7, Ubiquitin conjugating enzyme UbcH7

Cat. No. 62-0042-020
Lot. No. 30021

Quantity: 20 µg
Storage: -70°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS



CERTIFICATE OF ANALYSIS Page 1 of 2

Background

The enzymes of the ubiquitylation pathway play a pivotal role in a number of cellular processes including regulated and targeted proteasomal degradation of substrate proteins. Three classes of enzymes are involved in the process of ubiquitylation; activating enzymes (E1s), conjugating enzymes (E2s) and protein ligases (E3s). UBE2L3 is a member of the E2 conjugating enzyme family and cloning of the human gene was first described by Moynihan *et al.* (1996). Human UBE2L3 has been mapped to chromosome 22q11.2-q13.1 and shares 97% homology with its mouse homologue (Moynihan *et al.*, 1996; Moynihan *et al.*, 1998). UBE2L3 efficiently mediates the ubiquitylation of E6AP (Nuber *et al.*, 1996). A protein complex comprising UBE2L3, the E3 ligase Parkin and alpha synuclein (alpha-Sp22) has been identified in which the substrate alpha-Sp22 becomes polyubiquitylated in normal human brains and targeted for degradation. Loss of Parkin function causes pathologic accumulation of alpha-Sp22 in the brain which is associated with Parkinson's disease (Shimura *et al.*, 2001). UBE2L3 acts with E6-associated protein (E6-AP) to synergistically enhance the transcriptional activity of the progesterone receptor (PR) and increase its interaction with the steroid receptor coactivator 1 (SRC-1) (Verma *et al.*, 2004). Binding of UBE2L3

Continued on page 2

Physical Characteristics

Species: human

Source: *E. coli* expression

Quantity: 20 µg

Concentration: 1 mg/ml

Formulation: 50 mM HEPES pH 7.5,
150 mM sodium chloride, 2 mM
dithiothreitol, 10% glycerol

Molecular Weight: ~18 kDa

Purity: >98% by InstantBlue™ SDS-PAGE

Stability/Storage: 12 months at -70°C;
aliquot as required

Protein Sequence:

GSMAASRRLLMKELEEIRKCGMKNF
RNIQVDEANLLTWQGLIVPDNPPYDKGAFRIE
INFPAEYFPKPKKITFKTKIYHPNIDEKGQV
CLPVISAENWKPKATKTDQVIQSLIALVND
PQPEHPLRADLAEYYSKDRKKFCKNAEEFTK
KYGEKRPVD

The residues underlined remain after cleavage and removal of the purification tag.


UBE2L3 (regular text): Start **bold italics** (amino acid residues 1-154)

Accession number: AAH53368

Quality Assurance

Purity:

4-12% gradient SDS-PAGE
InstantBlue™ staining
Lane 1: MW markers
Lane 2: 1 µg UBE2L3



Protein Identification:

Confirmed by mass spectrometry.

E2-Ubiquitin Thioester Loading Assay:

The activity of UBE2L3 was validated by loading E1 UBE1 activated ubiquitin onto the active cysteine of the UBE2L3 E2 enzyme via a transthioesterification reaction. Incubation of the UBE1 and UBE2L3 enzymes in the presence of ubiquitin and ATP at 30°C was compared at two time points, T₀ and T₁₀ minutes. Sensitivity of the ubiquitin/UBE2L3 thioester bond to the reducing agent DTT was confirmed.



www.ubiquigent.com
Dundee, Scotland, UK

ORDERS / SALES SUPPORT

International: +1-617-245-0003
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)
Email: sales.support@ubiquigent.com

UK HQ and TECHNICAL SUPPORT

International: +44 (0) 1382 381147 (9AM-5PM UTC)
US/Canada: +1-617-245-0020 (9AM-5PM UTC)
Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2011. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0

UBE2L3 (UbcH7) [untagged]

E2 – Ubiquitin Conjugating Enzyme

Alternate Names: E2-F1, EC 6.3.2.19, L-UBC, UbcH7, UbcM4, Ubiquitin conjugating enzyme E2-18 kDa UbcH7, Ubiquitin conjugating enzyme UbcH7

Cat. No. 62-0042-020
Lot. No. 30021

Quantity: 20 µg
Storage: -70°C



FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS

CERTIFICATE OF ANALYSIS Page 2 of 2

Background

Continued from page 1

to the amino-terminal domain (NTD) of SMAD 7 stimulates E3 ligase Smurf activity via its HECT domain; recruitment of the complex to the TGFbeta receptor facilitates receptor degradation during TGFbeta signalling (Ogunjimi *et al.*, 2005). Changes in levels of UBE2L3 during the cell cycle regulate entrance into and progression through S phase. UBE2L3 levels decrease during S-phase but are restored in G2, it is thought progression into G2 occurs by UBE2L3 modulation of the intra-S phase checkpoint mediated by Chk1 (Whitcomb *et al.*, 2009).

References:

Moynihan TP, Ardley HC, Leek JP, Thompson J, Brindle NS, Markham AF, Robinson PA (1996) Characterization of a human ubiquitin-conjugating enzyme gene UBE2L3. *Mamm Genome* 7, 520-5.

Moynihan TP, Cole CG, Dunham I, O'Neil L, Markham AF, Robinson PA (1998) Fine-mapping, genomic organization, and transcript analysis of the human ubiquitinconjugating enzyme gene UBE2L3. *Genomics* 51, 124-7.

Nuber U, Schwarz S, Kaiser P, Schneider R, Scheffner M (1996) Cloning of human ubiquitin-conjugating enzymes UbcH6 and UbcH7 (E2-F1) and characterization of their interaction with E6-AP and RSP5. *J Biol Chem* 271, 2795-800.

Ogunjimi AA, Briant DJ, Pece-Barbara N, Le Roy C, Di Guglielmo GM, Kavsak P, Rasmussen RK, Seet BT, Sicheri F, Wrana JL (2005) Regulation of Smurf2 ubiquitin ligase activity by anchoring the E2 to the HECT domain. *Mol Cell* 19, 297-308.

Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ (2001) Ubiquitination of a new form of alphasynuclein by parkin from human brain: implications for Parkinson's disease. *Science* 293, 263-9.

Verma S, Ismail A, Gao X, Fu G, Li X, O'Malley BW, Nawaz Z (2004) The ubiquitin-conjugating enzyme UbcH7 acts as a coactivator for steroid hormone receptors. *Mol Cell Biol* 24, 8716-26.

Whitcomb EA, Dudek EJ, Liu Q, Taylor A (2009) Novel control of S phase of the cell cycle by ubiquitin-conjugating enzyme H7. *Mol Biol Cell* 20, 1-9.



www.ubiquigent.com
Dundee, Scotland, UK

ORDERS / SALES SUPPORT

International: +1-617-245-0003
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)
Email: sales.support@ubiquigent.com

UK HQ and TECHNICAL SUPPORT

International: +44 (0) 1382 381147 (9AM-5PM UTC)
US/Canada: +1-617-245-0020 (9AM-5PM UTC)
Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2011. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0